All In Biotech

Drug Trial Radar · NCT07931495

A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Diet and Exercise

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Nov 10, 2026

Primary completion

Jun 5, 2028

Study completion Aug 28, 2028

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to look at how well zenagamtide lowers blood sugar levels and body weight in people with type 2 diabetes when compared to placebo. Participants will either get zenagamtide, the treatment being tested or placebo, a treatment that has no active medicine in it. Which treatment participants get is decided by chance. Zenagamtide is a new medicine that doctors cannot prescribe yet, but it has been tested in humans before.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • ZenagamtideDrug

    Zenagamtide will be administered subcutaneously once weekly.

  • PlaceboDrug

    Placebo matched to zenagamtide will be administered subcutaneously once weekly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in glycated haemoglobin (HbA1c)Time frame: From baseline (week 0) to week 44

Locations

48 sites in 8 countries. Site status is shown where the registry gives one.

  • Ark Clinical Research

    Fountain Valley, California

  • Los Angeles Institute for Metabolic Research

    Los Angeles, California

  • Encompass Clinical Research_Spring Valley

    Spring Valley, California

  • Encore Medical Research LLC

    Hollywood, Florida

  • My Preferred Research

    Miami, Florida

  • Florida Institute for Clinical research

    Orlando, Florida

  • Encore Medical Research of Weston

    Weston, Florida

  • Brigham & Women's Hospital

    Boston, Massachusetts

  • Accellacare

    Wilmington, North Carolina

  • Preferred Primary Care physicians Washington

    Washington, Pennsylvania

  • Southwest Clinical Trials

    Houston, Texas

  • Pinnacle Clinical Research

    San Antonio, Texas

  • Chongqing University Three Gorges Hospital-Endocrinology

    Chongqing, Chongqing Municipality, China

  • The Second Affiliated Hospital of Nanjing Medical University-Endocrinology

    Nanjing, Jiangsu, China

  • The Affiliated Hospital of Jiangsu University-Endocrinology

    Zhenjiang, Jiangsu, China

  • Jinan Central Hospital-General Medicine

    Jinan, Shandong, China

  • Tianjin Medical University Chu Hsien-I Memorial Hospital-Department of Metabolism

    Tianjin, Tianjin Municipality, China

  • Akaicho Clinic_Internal medicine

    Chiba-shi, Chiba, Japan

  • Tokyo-Eki Center-building Clinic_Internal Medicine

    Tokyo, Japan

  • Fukuwa Clinic_Internal Medicine

    Tokyo, Japan

  • ToCROM Clinic_Internal Medicine

    Tokyo, Japan

  • OCROM Clinic_Internal medicine

    Suita-shi, Osaka, Japan

  • Pro Familia Altera Sp. z o.o.

    Katowice, Poland

  • Centrum Badawcze Panaceum Agnieszka Brzezicka Magdalena Lenkiewicz Sp. z o.o.

    Malbork, Poland

  • Formed 2 Sp. z o.o.

    Oświęcim, Poland

  • Velocity Nova Sp. z o.o.

    Staszów, Poland

  • Balticmed Świnoujście Sp. z o. o.

    Świnoujście, Poland

  • NBR Polska Tomasz Klodawski

    Warsaw, Poland

  • Cbk Med Clinic Sp. z o.o.

    Płock, Masovian Voivodeship, Poland

  • Solace Clinical Research

    San Juan, Puerto Rico

  • SC Nutrilife SRL

    Bucharest, Romania

  • Institutul De Pneumoftiziologie Marius Nasta

    Bucharest, Romania

  • SC Gensan SRL, Policlinica ASTRA

    Sibiu, Romania

  • Diabdana S.R.L.

    Oradea, Bihor County, Romania

  • Poli Cardinal Med Srl

    Reghin, Mureș County, Romania

  • Sc Mediab Srl

    Târgu Mureş, Mureș County, Romania

  • KARDIO-SANUS, spol. s r.o.

    Bratislava, Slovakia

  • Diab - Int, s.r.o.

    Bytča, Slovakia

  • Univerzitna nemocnica L. Pasteura Kosice

    Košice, Slovakia

  • FUNKYSTUFF s.r.o

    Nové Zámky, Slovakia

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.